海尔生物(688139) - 2021 Q2 - 季度财报

Financial Performance - Operating revenue rose by 56.05% to CNY 927,954,150.02 compared to the same period last year[10] - Net profit attributable to shareholders increased by 270.06% to CNY 573,077,466.11 compared to the same period last year[10] - The net profit after deducting non-recurring gains and losses increased by 82.47% to CNY 214,999,373.27 compared to the same period last year[10] - Basic earnings per share increased by 269.39% to CNY 1.81 compared to the same period last year[10] - The weighted average return on equity increased by 12.79 percentage points to 18.93% compared to the same period last year[10] Assets and Shareholder Equity - Total assets increased by 15.38% to CNY 4,548,820,465.63 compared to the end of the previous year[10] - The net assets attributable to shareholders increased by 16.99% to CNY 3,247,598,089.13 compared to the end of the previous year[10] Cash Flow and Expenditure - The net cash flow from operating activities decreased by 6.84% to CNY 216,874,817.07 compared to the same period last year[10] - Research and development expenditure accounted for 9.98% of operating revenue, an increase of 0.12 percentage points compared to the same period last year[10] Shareholder Information - The total number of shareholders reached 10,658 at the end of the reporting period[12]